The effect of linagliptin on glycaemic control and tolerability in patients with type 2 diabetes mellitus: a systematic review and meta-analysis

Diabetes, Obesity & Metabolism
D Singh-FrancoC Harrington

Abstract

Linagliptin is a new dipeptidyl peptidase-4 inhibitor recently approved for use in the USA. The objective of this systematic review and meta-analysis was to assess effect of linagliptin on glycaemic control, biomarkers and incidence of adverse events (AEs) in patients with type 2 diabetes mellitus. Five published and four unpublished randomized, clinical trials were identified from multiple databases. Qualitative assessments and quantitative analyses were performed. Nine studies included 4246 participants with 53% men, 59.4% Caucasians, 38.7% Asians, and age range 45-69 years. Linagliptin was given as monotherapy (vs. placebo) or combined with metformin (vs. metformin + placebo), sulphonylurea (vs. sulphonylurea + placebo) or pioglitazone (vs. pioglitazone + placebo). Linagliptin 5 mg/day for 12-24 weeks, significantly reduced haemoglobin A1c (HbA1c) (-0.63%, p < 0.00001), fasting plasma glucose (FPG) (-1.01 mmol/l, p < 0.00001) and improved disposition index (DI, product of insulin sensitivity and acute insulin secretion) (p = 0.0001). Linagliptin monotherapy was not more effective than metformin at reducing HbA1c or FPG. Similar proportion of patients in linagliptin and placebo groups reported AEs including upper respiratory ...Continue Reading

References

May 25, 2002·European Journal of Clinical Investigation·R N BergmanS E Kahn
May 31, 2003·BMJ : British Medical Journal·Joel LexchinOtavio Clark
Aug 21, 2003·JAMA : the Journal of the American Medical Association·Bodil Als-NielsenLise L Kjaergard
Mar 27, 2009·The American Journal of the Medical Sciences·Daniel M RicheKrista D Riche
Jan 21, 2010·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Stefan BlechKlaus Wagner
Feb 11, 2011·Diabetes/metabolism Research and Reviews·Matteo MonamiEdoardo Mannucci
Feb 22, 2011·Gastroenterology·Michael ElashoffPeter C Butler
Mar 2, 2013·Diabetes & Vascular Disease Research : Official Journal of the International Society of Diabetes and Vascular Disease·Julio RosenstockHans-Jürgen Woerle
May 2, 2013·The Journal of Clinical Endocrinology and Metabolism·Payal ShahKathrin Maedler

❮ Previous
Next ❯

Citations

Sep 24, 2013·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Jaime A Davidson
Oct 5, 2012·Diabetes, Obesity & Metabolism·D Singh-FrancoJ McLaughlin-Middlekauff
Oct 5, 2012·Diabetes, Obesity & Metabolism·D R OwensH-J Woerle
Feb 5, 2013·Expert Opinion on Drug Metabolism & Toxicology·André J Scheen
Feb 21, 2013·Expert Opinion on Drug Safety·André J Scheen
Mar 16, 2016·The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care·Solène Schirr-BonnansLaurent Molinier
Jul 16, 2015·Clinical and Experimental Pharmacology & Physiology·Xiao-Wu ChenShu-Feng Zhou
Sep 23, 2016·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Han ChenGuoxin Zhang
Mar 21, 2013·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·Guillermo E Umpierrez, Luigi Meneghini
Jun 6, 2020·The Cochrane Database of Systematic Reviews·Filip GnesinBianca Hemmingsen
Oct 16, 2013·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·Jaime A Davidson

❮ Previous
Next ❯

Related Concepts

Related Feeds

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.